semaglutide for diabetes wichita FDA Clears Cardiac Risk Reduction in Diabetic Patients GLP-1s | AgelessRx

Wegovy also reduces the risk of major adverse cardiovascular events in adults with obesity or overweight and existing cardiovascular disease

More severe but less common side effects include pancreatitis, changes in vision, and kidney problems

Many millions of dollars therefore are now also invested to market the new agents, reminiscent of the period that followed the launch of the most recent new class of drugs for type 2 diabetes, the peroxisome proliferatoractivated receptor- (PPAR-) agonists

Like any medication, however, some people should not use them

Here is how the numbers shift based on behavior: The takeaway is direct: your habits control the ratio and your physique

The GLP-1 gold rush is just getting started